Dirk Van Raemdonck1, Shaf Keshavjee2, Bronwyn Levvey3, Wida S Cherikh4, Greg Snell3, Michiel Erasmus5, André Simon6, Allan R Glanville7, Stephen Clark8, Frank D'Ovidio9, Pedro Catarino10, Kenneth McCurry11, Marshall I Hertz12, Rajamiyer Venkateswaran13, Peter Hopkins14, Ilhan Inci15, Rajat Walia16, Daniel Kreisel17, Jorge Mascaro18, Daniel F Dilling19, Philip Camp20, David Mason21, Michael Musk22, Michael Burch23, Andrew Fisher8, Roger D Yusen17, Josef Stehlik24, Marcelo Cypel2. 1. University Hospitals Leuven, Leuven, Belgium. Electronic address: dirk.vanraemdonck@uzleuven.be. 2. University of Toronto, Toronto, Ontario, Canada. 3. Alfred Hospital, Melbourne, Victoria, Australia. 4. United Network for Organ Sharing, Richmond, Virginia. 5. University Medical Center Groningen, Groningen, The Netherlands. 6. Harefield Hospital, London, United Kingdom. 7. St Vincent's Hospital, Sydney, New South Wales, Australia. 8. Freeman Hospital, Newcastle upon Tyne, United Kingdom. 9. Columbia University Presbyterian Hospital, New York, New York. 10. Royal Papworth Hospital, Cambridge, United Kingdom. 11. Cleveland Clinic, Cleveland, Ohio. 12. University of Minnesota, Minneapolis, Minnesota. 13. Wythenshawe Hospital, Manchester, United Kingdom. 14. The Prince Charles Hospital, Brisbane, Australia. 15. University Hospital Zurich, Zurich, Switzerland. 16. St. Joseph's Hospital & Medical Center, Phoenix, Arizona. 17. Washington University, St Louis, Missouri. 18. University Hospitals Birmingham, Birmingham, United Kingdom. 19. Loyola University Medical Center, Chicago, Illinois. 20. Brigham and Womens Hospital, Boston, Massachusetts. 21. Baylor University Medical Center, Dallas, Texas. 22. Fiona Stanley Hospital, Perth, Australia. 23. Great Ormond Street for Children, London, United Kingdom. 24. University of Utah, Salt Lake City, Utah.
Abstract
BACKGROUND: This study aimed to examine intermediate-term outcomes of lung transplantation (LTx) recipients from donors after circulatory death (DCD). METHODS: We examined the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Transplant Registry data for patients transplanted between January 2003 and June 2017 at 22 centers in North America, Europe, and Australia participating in the DCD Registry. The distribution of continuous variables was summarized as median and interquartile range (IQR) values. Wilcoxon rank sum test was used to compare distribution of continuous variables and chi-square or Fisher's exact test for categorical variables. Kaplan-Meier survival rates after LTx from January 2003 to June 2016 were compared between DCD-III (Maastricht category III withdrawal of life-sustaining therapy [WLST]) only and donors after brain death (DBD) using the log-rank test. Risk factors for 5-year mortality were investigated using Cox multivariate proportional-hazards model. RESULTS: The study cohort included 11,516 lung transplants, of which 1,090 (9.5%) were DCD lung transplants with complete data. DCD-III comprised 94.1% of the DCD cohort. Among the participating centers, the proportion of DCD-LTx performed each year increased from 0.6% in 2003 to 13.5% in 2016. DCD donor management included extubation in 91%, intravenous heparin in 53% and pre-transplant normothermic ex vivo donor lung perfusion in 15%. The median time interval from WLST to cardiac arrest was 15 minutes (IQR: 11-22 minutes) and to cold flush 32 minutes (IQR: 26-41minutes). Compared with DBD, donor age was higher in DCD-III donors (46 years [IQR: 34-55] vs 40 years [IQR: 24-52]), bilateral LTx was performed more often (88.3% vs 76.6%), and more recipients had chronic obstructive pulmonary disease and emphysema as their transplant indication. Five-year survival rates were comparable (63% vs 61%, p = 0.72). In multivariable analysis, recipient and donor ages, indication diagnosis, procedure type (single vs bilateral and double LTx), and transplant era (2003-2009 vs 2010-2016) were independently associated with survival (p < 0.001), but donor type was not (DCD-III vs DBD; hazard ratio, 1.04 [0.90-1.19], p = 0.61). CONCLUSION: This ISHLT DCD Registry report with 5-year follow-up demonstrated similar favorable long-term survival in DCD-III and DBD lung donor recipients at 22 experienced centers globally. These data indicate that more extensive use of DCD-LTx would increase donor organ availability and may reduce waiting list mortality.
BACKGROUND: This study aimed to examine intermediate-term outcomes of lung transplantation (LTx) recipients from donors after circulatory death (DCD). METHODS: We examined the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Transplant Registry data for patients transplanted between January 2003 and June 2017 at 22 centers in North America, Europe, and Australia participating in the DCD Registry. The distribution of continuous variables was summarized as median and interquartile range (IQR) values. Wilcoxon rank sum test was used to compare distribution of continuous variables and chi-square or Fisher's exact test for categorical variables. Kaplan-Meier survival rates after LTx from January 2003 to June 2016 were compared between DCD-III (Maastricht category III withdrawal of life-sustaining therapy [WLST]) only and donors after brain death (DBD) using the log-rank test. Risk factors for 5-year mortality were investigated using Cox multivariate proportional-hazards model. RESULTS: The study cohort included 11,516 lung transplants, of which 1,090 (9.5%) were DCD lung transplants with complete data. DCD-III comprised 94.1% of the DCD cohort. Among the participating centers, the proportion of DCD-LTx performed each year increased from 0.6% in 2003 to 13.5% in 2016. DCD donor management included extubation in 91%, intravenous heparin in 53% and pre-transplant normothermic ex vivo donor lung perfusion in 15%. The median time interval from WLST to cardiac arrest was 15 minutes (IQR: 11-22 minutes) and to cold flush 32 minutes (IQR: 26-41minutes). Compared with DBD, donor age was higher in DCD-III donors (46 years [IQR: 34-55] vs 40 years [IQR: 24-52]), bilateral LTx was performed more often (88.3% vs 76.6%), and more recipients had chronic obstructive pulmonary disease and emphysema as their transplant indication. Five-year survival rates were comparable (63% vs 61%, p = 0.72). In multivariable analysis, recipient and donor ages, indication diagnosis, procedure type (single vs bilateral and double LTx), and transplant era (2003-2009 vs 2010-2016) were independently associated with survival (p < 0.001), but donor type was not (DCD-III vs DBD; hazard ratio, 1.04 [0.90-1.19], p = 0.61). CONCLUSION: This ISHLT DCD Registry report with 5-year follow-up demonstrated similar favorable long-term survival in DCD-III and DBD lung donor recipients at 22 experienced centers globally. These data indicate that more extensive use of DCD-LTx would increase donor organ availability and may reduce waiting list mortality.
Authors: Pedro Augusto Reck Dos Santos; Paulo José Zimermann Teixeira; Daniel Messias de Moraes Neto; Marcelo Cypel Journal: J Bras Pneumol Date: 2022-04-20 Impact factor: 2.800
Authors: Avnish K Seth; Ravi Mohanka; Sumana Navin; Alla Gk Gokhale; Ashish Sharma; Anil Kumar; Bala Ramachandran; K R Balakrishnan; Darius Mirza; Dhvani Mehta; Kapil G Zirpe; Kumud Dhital; Manisha Sahay; Srinagesh Simha; Radha Sundaram; Rahul Pandit; Raj K Mani; Roop Gursahani; Subash Gupta; Vivek B Kute; Sunil Shroff Journal: Indian J Crit Care Med Date: 2022
Authors: Zhizhou Yang; William D Gerull; Hailey M Shepherd; Gary F Marklin; Tsuyoshi Takahashi; Bryan F Meyers; Benjamin D Kozower; G Alexander Patterson; Ruben G Nava; Ramsey R Hachem; Chad A Witt; Derek E Byers; Rodrigo Vazquez Guillamet; Michael K Pasque; Yan Yan; Daniel Kreisel; Varun Puri Journal: Am J Transplant Date: 2021-03-11 Impact factor: 9.369
Authors: Beatriz Domínguez-Gil; Nancy Ascher; Alexander M Capron; Dale Gardiner; Alexander R Manara; James L Bernat; Eduardo Miñambres; Jeffrey M Singh; Robert J Porte; James F Markmann; Kumud Dhital; Didier Ledoux; Constantino Fondevila; Sarah Hosgood; Dirk Van Raemdonck; Shaf Keshavjee; James Dubois; Andrew McGee; Galen V Henderson; Alexandra K Glazier; Stefan G Tullius; Sam D Shemie; Francis L Delmonico Journal: Intensive Care Med Date: 2021-02-26 Impact factor: 17.440
Authors: Alessandro Palleschi; Lorenzo Rosso; Giulia Maria Ruggeri; Giorgio Alberto Croci; Valeria Rossetti; Giuseppe Citerio; Giacomo Grasselli; Mario Nosotti; Alberto Zanella Journal: Transplantation Date: 2021-12-01 Impact factor: 5.385
Authors: Thomas M Egan; Benjamin E Haithcock; Jason Lobo; Gita Mody; Robert B Love; John Jacob Requard; John Espey; Mir Hasnain Ali Journal: J Thorac Dis Date: 2021-11 Impact factor: 3.005